GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $1.83 billion. The enterprise value is $1.86 billion.
| Market Cap | 1.83B |
| Enterprise Value | 1.86B |
Important Dates
The next confirmed earnings date is Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 29.82 million shares outstanding. The number of shares has increased by 2.38% in one year.
| Current Share Class | 29.82M |
| Shares Outstanding | 29.82M |
| Shares Change (YoY) | +2.38% |
| Shares Change (QoQ) | +1.28% |
| Owned by Insiders (%) | 1.86% |
| Owned by Institutions (%) | 82.30% |
| Float | 20.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 92.41 |
| PS Ratio | 4.02 |
| Forward PS | 3.39 |
| PB Ratio | 7.48 |
| P/TBV Ratio | 18.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.30, with a Debt / Equity ratio of 0.69.
| Current Ratio | 3.30 |
| Quick Ratio | 2.90 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.00 |
Financial Efficiency
Return on equity (ROE) is -40.80% and return on invested capital (ROIC) is -22.49%.
| Return on Equity (ROE) | -40.80% |
| Return on Assets (ROA) | -7.89% |
| Return on Invested Capital (ROIC) | -22.49% |
| Return on Capital Employed (ROCE) | -14.67% |
| Weighted Average Cost of Capital (WACC) | 13.93% |
| Revenue Per Employee | $349,558 |
| Profits Per Employee | -$81,813 |
| Employee Count | 1,300 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 9.35 |
Taxes
In the past 12 months, GeneDx Holdings has paid $62,000 in taxes.
| Income Tax | 62,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.46% in the last 52 weeks. The beta is 1.97, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.97 |
| 52-Week Price Change | -52.46% |
| 50-Day Moving Average | 80.01 |
| 200-Day Moving Average | 72.93 |
| Relative Strength Index (RSI) | 38.67 |
| Average Volume (20 Days) | 838,579 |
Short Selling Information
The latest short interest is 5.63 million, so 18.87% of the outstanding shares have been sold short.
| Short Interest | 5.63M |
| Short Previous Month | 5.88M |
| Short % of Shares Out | 18.87% |
| Short % of Float | 27.52% |
| Short Ratio (days to cover) | 7.71 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $454.43 million and -$106.36 million in losses. Loss per share was -$3.64.
| Revenue | 454.43M |
| Gross Profit | 315.30M |
| Operating Income | -59.67M |
| Pretax Income | -106.30M |
| Net Income | -106.36M |
| EBITDA | -33.70M |
| EBIT | -59.67M |
| Loss Per Share | -$3.64 |
Balance Sheet
The company has $132.55 million in cash and $167.40 million in debt, with a net cash position of -$34.85 million or -$1.17 per share.
| Cash & Cash Equivalents | 132.55M |
| Total Debt | 167.40M |
| Net Cash | -34.85M |
| Net Cash Per Share | -$1.17 |
| Equity (Book Value) | 244.22M |
| Book Value Per Share | 8.19 |
| Working Capital | 171.73M |
Cash Flow
In the last 12 months, operating cash flow was -$48.71 million and capital expenditures -$27.09 million, giving a free cash flow of -$75.80 million.
| Operating Cash Flow | -48.71M |
| Capital Expenditures | -27.09M |
| Depreciation & Amortization | 25.98M |
| Net Borrowing | 35.37M |
| Free Cash Flow | -75.80M |
| FCF Per Share | -$2.54 |
Margins
Gross margin is 69.38%, with operating and profit margins of -13.13% and -23.40%.
| Gross Margin | 69.38% |
| Operating Margin | -13.13% |
| Pretax Margin | -23.39% |
| Profit Margin | -23.40% |
| EBITDA Margin | -7.41% |
| EBIT Margin | -13.13% |
| FCF Margin | n/a |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.38% |
| Shareholder Yield | -2.38% |
| Earnings Yield | -5.94% |
| FCF Yield | -4.15% |
Analyst Forecast
The average price target for GeneDx Holdings is $93.50, which is 52.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $93.50 |
| Price Target Difference | 52.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 19.39% |
| EPS Growth Forecast (3Y) | 8.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:33 |
Scores
GeneDx Holdings has an Altman Z-Score of 3.98 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.98 |
| Piotroski F-Score | 4 |